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Introduction
Metabolic syndrome (MetS), known as insulin resistance syn-
drome, is characterized by a cluster of cardiovascular risk factors 
such as hypertension, glucose intolerance, high triglycerides, and 
low high density lipoprotein-cholesterol (HDL-C) concentrations.1) 
MetS confers an increased risk for vascular disease-associated mor-
bidity and mortality as well as all-cause mortality, even in the abs-
ence of clinically evident cardiovascular disease (CVD) and/or dia-
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Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, such as hypertension, glucose intolerance, high tri-
glycerides, and a low high density lipoprotein-cholesterol level. MetS is known to be associated with cardiovascular diseases. In order to 
diagnose MetS, definitions such as National Cholesterol Education Program Adult Treatment Panel III, American Heart Association/Na-
tional Heart Lung and Blood Institute, International Diabetes Federation, World Health Organization, European Group for the Study of Insu-
lin Resistance and American College of Endocrinology are widely used. However, using different criteria may lead to confusion regarding 
the diagnosis and treatment of patients with MetS in the primary care setting. Our objected was to review 3 aspects concerning MetS us-
ing the Metabolic Syndrome Research Initiatives study of 123892 healthy Koreans (1994-2001) that had a maximum follow-up of 12 years. 
The 3 aspects were reviewed by determination of the association of MetS with the development of atherosclerotic cardiovascular disease 
(ASCVD) and ischemic heart disease (IHD). Based on our findings, each metabolic factor associated with MetS was not weighted equally. 
The hazard ratio (HR) was higher in individuals with higher glucose compared with the HR in individuals with higher body mass index. In-
dividuals with pre-MetS (having 1 or 2 metabolic factors) had 1.5-2.3 fold higher risk of developing ASCVD and IHD in both genders. In the pres-
ence of MetS, both singly and in combination, precede the development of ASCVD and IHD and individuals with pre-MetS must not be ig-
nored as there is no apparent threshold in defining MetS. Furthermore, MetS may complement the Framingham Risk Score and can be used 
as the first line approach to treat the ASCVD or IHD. (Korean Circ J 2012;42:371-378)
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betes mellitus (DM).2-5) Several organizations have established their 
own diagnostic criteria for MetS.6) In 1998, the World Health Organiz-
ation (WHO) standardized a definition of MetS.7) This was revised in 
1999 after consultation with the European Group for the Study of 
Insulin Resistance (EGIR).8) In 2003, the American College of Endo-
crinology (ACE) provided a new definition of MetS.9) However, the 
number of risk factors needed for the diagnosis of the MetS has 
not specified in the ACE definition.9) Therefore in 2001, the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
III) proposed a practical definition of MetS.10) This was adopted by 
the Third Joint Task Force of European and Other Societies on Car-
diovascular Disease Prevention in Clinical Practice in 2003.11) The In-
ternational Diabetes Federation (IDF), the American Heart Associa-
tion (AHA), and the National Heart Lung and Blood Institute (NHLBI) 
issued each diagnostic criteria for the MetS.12) These definitions re-
tained most of the NCEP ATP III criteria and AHA/NHLBI suggested 
an adjustment of waist circumference to lower thresholds only in 
some ethnic groups, such as Asians, as well as a lower threshold 
for elevated fasting glucose (≥100 mg/dL).12)
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In fact, different combinations of following metabolic factors 
are required in each definition of the MetS, including: insulin resis-
tance, dysglycemia, low HDL-C, hypertriglyceridemia, obesity or in-
creased waist circumference, hypertension, impaired glucose toler-
ance or DM, microalbuminuria, and hyperinsulinemia (Table 1). Fur-
thermore, the importance of each metabolic factor is different in 
each diagnostic criteria of the MetS. For example, the NCEP ATP III 
considers that each metabolic factor has the same importance,10) 
whereas the WHO requires impaired glucose tolerance among its 
criteria to diagnose MetS.7) The EGIR definition includes insulin de-
termination as an essential component.8) Therefore, this may lead 
to confusion regarding the diagnosis and treatment of the MetS in 
the primary care setting when patients are being diagnosed using 
different criteria.13)
In addition, MetS was found to be inferior to the Framingham Risk 
Score (FRS) in predicting either type 2 DM or CVD from previous 
studies. Nonetheless, MetS predicted both type 2 DM, CVD, and 
vascular diseases.14) While it has not been established whether MetS 
is a better predictor of diseases, such as type 2 DM, CVD, and other 
vascular diseases, MetS may be a good all-purpose predictor com-
pared with the FRS.15) Therefore, we intended to review 3 aspects 
that primarily concerned MetS using the Metabolic Syndrome Re-
Table 1. Definition, importance of each metabolic factors and limitations of each metabolic syndrome diagnostic criteria
Definitions Importance Limitations
NCEP-ATP III 
(2001)
≥3 risk  determinants
1. Waist circumference ≥90 cm (M) and 80 cm (F)
2. Triglyceride ≥150 mg/dL
3. HDL-C <40 mg/dL (M) and 50 mg/dL (F)
4. Blood pressure ≥130/85 mm Hg or medication
5. Fasting plasma glucose ≥110 mg/dL (include diabetes)
Each metabolic
  factors has the same
  importance
•  No measurement of 
 insulin resistance
•  No determination of 
 glucose tolerance 
•  No inclusion of type 2 
 diabetes
AHA/
NHLBI (2005)
≥3 risk  determinants
1. Waist circumference ≥90 cm (M) and 80 cm (F)
2. Triglyceride ≥150 mg/dL or under treatment 
3. HDL-C <40 mg/dL (M) and 50 mg/dL (F)
4. Blood pressure ≥130/85 mm Hg or medication
5. Fasting plasma glucose ≥100 mg/dL (include diabetes)
Each metabolic
  factors has the same
  importance
•  No measurement of 
 insulin resistance
•  No determination of 
 glucose tolerance 
•  No inclusion of type 2 
 diabetes
IDF (2005)
Waist circumference ≥90 cm (M) and 80 cm (F) plus any 2 of followings
1. Triglyceride ≥150 mg/dL or under treatment
2. HDL-C <40 mg/dL (M) and 50 mg/dL (F) or under treatment
3. Blood pressure ≥130/85 mm Hg or medication
4. Fasting plasma glucose ≥100 mg/dL or history of diabetes or medication
It requires obesity
  (central obesity)
For diagnosis of
  metabolic syndrome
It does not essentially 
  require insulin 
  resistance
WHO (1998)
IGT, IFG, T2DM or lowered IS plus any 2 of following
1. Waist/Hip ratio >0.90 (M) and 0.85 (F) and/or Body mass index >30 kg/m2
2. Triglyceride ≥150 mg/dL 
3. Blood pressure ≥160/90 mm Hg or medication
4. HDL-C <35 mg/dL (M) and 39 mg/dL (F)
5. Microalbuminuria ≥20 µg/min
It requires diabetes, 
  IGT or insulin resistance 
  for diagnosis of 
  metabolic syndrome
The special testing of 
  glucose status beyond
  routine clinical 
  assessment may be 
  necessary to diagnose 
  metabolic syndrome
EGIR (2001)
Insulin >95th percentile plus any 2 of following 
1. Waist circumference ≥94 cm (M) and 80 cm (F)
2. Triglyceride ≥150 mg/dL and/or HDL-C <39 mg/dL (M,F)
3. Blood pressure ≥140/90 mm Hg or medication
4. IGT or IFG (but not diabetes)
Inclusion of insulin 
  determination as an 
  essential components
No inclusion of 
  diabetes mellitus
AACE (2003)
IGT or IFG plus any of the following based on clinical judgment 
1. Body mass index ≥25 kg/m2
2. Triglyceride ≥150 mg/dL and HDL-C <40 mg/dL (M) or 50 mg/dL (F)
3. Blood pressure ≥130/85 mm Hg
4. IGT or IFG (but not diabetes)
5. Other features* of insulin resistance
It requires IGT or 
  IFG for diagnosis 
  of metabolic 
  syndrome
•  No inclusion of diabetes
•  No defined number of 
 risk factor is specified; 
 diagnosis is left to clinical 
 judgement
*Other features in AACE include: polycystic ovary syndrome; sedentary lifestyle; age; ethnicity (certain groups); and family history of type 2 diabetes, hy-
pertension, or cardiovascular disease. HDL-C: high density lipoprotein-cholesterol, IS: insulin resistance, IGT: impaired glucose tolerance, IFG: impaired fast-
ing glucose, T2DM: type 2 diabetes mellitus 
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search Initiatives (MSRI) study of Koreans with a maximum follow-
up of 12 years. Three aspects regarding MetS are as follows: 1) each 
metabolic factor has different importance; 2) there is an apparent 
threshold effect; 3) FRS is superior to MetS in relation to the risk of 
atherosclerotic cardiovascular disease (ASCVD), including myocar-
dial infarction (MI), ischemic heart disease (IHD), total stroke, hem-
orrhagic stroke and ischemic stroke.
 
Metabolic Syndrome Research Initiatives Study
This study included 123892 healthy Koreans (men: 67615, women: 
56277) aged 20-80 years, who visited the Health promotion centers 
for routine health examination from 1994 to 2001 located at both 
Severance hospital and Samsung hospital. Detailed purpose and 
methods of data collection were described in our previous study.16) 
General characteristics of study participants in the MSRI study are 
described in Table 2. 
For data collection, during a standardized examination at the 
Health promotion centers, their demographic characteristics such 
as age, gender, and family and past history of clinical diseases, cig-
arette smoking status (never smoker, ex-smoker and current smok-
er) and alcohol consumption status (never-drinker and ever-drink-
er) were collected via a standardized health questionnaire. Body 
mass index (BMI) was calculated as weight (kg) divided by the sq-
uare of height (m2). A waist circumference was measured midway 
between the lower rib and iliac crest. Systolic and diastolic blood 
pressures were measured in a seated position with a mercury sphyg-
momanometer or automatic manometer. In addition, MetS compo-
nents, such as fasting blood glucose, total cholesterol, triglyceride 
and HDL-C were measured using the Hitachi-7600 analyzer (Hitachi 
Ltd., Tokyo, Japan). 
The principal outcome variables were the incidence of ASCVD 
including MI, IHD, and stroke subtypes (ischemic, hemorrhagic, and 
total stroke), as recorded in hospital admission discharge records 
from 1994-2007. We ascertained these outcomes from health insur-
ance claim data from the National Health Insurance Corporation 
and checked fatal cases from the National death certificate data.17)18) 
MI, IHD, ischemic stroke, hemorrhagic and total stroke were de-
fined by the International Classification of Diseases 10th Revision 
codes: MI, I20; IHD, I20-I25; ischemic stroke, I63-I69; hemorrhagic 
stroke, I60-I62; total stroke, I60-I69. Morbidity was recorded accord-
ing to the International Classification of Diseases 10th Revision 
codes in a standardized manner.17-19) The accuracy rate of the Inter-
national Classification of Diseases codes for cerebrovascular diseases 
in medical claims for men in Korea was reported as 83.0% in 2000.20) 
Metabolic syndrome was defined by the Third report of the Na-
tional Cholesterol Education Program Expert Panel on Detection, Ev-
aluation and Treatment of High Blood Cholesterol in Adults (NCEP/
ATP III) and the AHA/NHLBI.10) High waist circumferences were de-
fined as ≥90 cm for men and ≥80 cm for women according to Asia-
Pacific criteria.21)
In the MSRI study, the prevalence of MetS was 23.8% among 
men and 16.8% among women. The prevalence of MetS increased 
with age but decreased among patients aged 70 and older than 70 
years. When compared the prevalence of MetS in the MSRI study 
with that in the Korean National Health and Nutrition Examination 
Survey, similar patterns of the prevalence of MetS were obtained 
(data not shown). For outcome variable incident events, the num-
Table 2. Baseline characteristics of study participants in the MSRI
Men
(n=67615)
Women
(n=56277)
Mean SD Mean SD
Age in years 47.1 10.8 47.1 11.2
Body mass index (kg/m2) 24.0 2.8 23.1 3.2
Waist circumference (cm) 84.2 8.1 75.6 8.8
Systolic blood pressure (mm Hg) 124.1 16.9 121.2 18.8
Diastolic blood pressure (mm Hg) 77.1 12.1 74.5 11.7
Total cholesterol (mg/dL) 197.4 34.7 195.5 37.1
Triglyceride (mg/dL) 158.8 100.9 115.8 75.5
HDL-C (mg/dL) 47.5 11.7 55.2 13.3
LDL-C (mg/dL) 121.3 32.3 119.7 33.4
Fasting serum glucose (mg/dL) 99.5 26.0 93.6 20.8
TG/HDL-C 3.7 3.2 2.4 2.2
N % N %
Smoking
Current smokers 34873 52.3 3339 6.2
Past smokers 18795 28.2 3668 6.8
Never smokers 12992 19.5 47272 87.1
Alcohol drinking
Current drinkers 53876 80.7 18187 33.5
Past drinkers 4346 6.5 3406 6.3
Never drinkers 8576 12.8 32768 60.3
Exercise
Current exerciser 39382 61.7 24457 46.9
Never exerciser 24482 38.3 27677 53.1
Past history
Hypertension 17402 25.7 12627 22.4
Diabetes 5024 7.4 2345 4.2
Medication
Hypertension 3795 6.4 3127 6.3
Diabetes 1552 2.6 890 1.8
All of the above differences were statistically significant (p<0.05) by t-test 
or chi-square test. TG: triglyceride, HDL-C: high density lipoprotein-choles-
terol, MSRI: Metabolic Syndrome Research Initiatives
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ber of incident events of outcome variables in this MSRI study is 
as follows: MI, 440 events in men, 122 events in women; IHD, 2255 
events in men, 1102 events in women; total stroke. There were 1597 
events in men, 1046 events in women; ischemic stroke, 1022 events 
in men, 626 events in women; hemorrhagic stroke, 356 events in 
men, 265 events in women; All ASCVD; 4153 events in men, and 
2560 events in women.
Pathophysiology
Metabolic syndrome seems to have 3 potential etiological cate-
gories: obesity and disorders of adipose tissue; insulin resistance; 
and a constellation of independent factors, such as molecules of 
hepatic, vascular, and immunologic origin, that mediate specific com-
ponents of the MetS.22)
Persons with MetS have at least a 2-fold increase in risk for AS-
CVD, compared to those without.23) However, the relationship be-
tween metabolic risk factors and development of ASCVD is com-
plex and certainly not well understood. Nonetheless, a brief review 
of hypothesized mechanisms may be of interest. The most common 
mechanisms in the development of ASCVD include atherogenic dy-
slipidemia and hyperglycemia.24) 
Atherogenic dyslipidemia is characterized by an increase in elevat-
ed triglyceride {increased very low-density lipoprotein (VLDL) particle 
number}, increased small low density lipoprotein (LDL) particles, and 
low HDL-C.10) For elevated triglyceride, triglyceride-rich lipoproteins 
were thought not to be atherogenic. However, smaller triglyceride-
rich lipoprotein is proven to be atherogenic by studies performed 
in laboratory animals, in meta-analysis of epidemiological studies, 
and in clinical trials.24) For small LDL particles, small LDL particles are 
a surrogate for an increased LDL particle number because the total 
number of lipoprotein particles in LDL fraction is usually increased 
in the presence of small LDL particles.25) A low HDL-C level is an-
other characteristic of atherogenic dyslipidemia.10) The increased 
number of VLDL and LDL particles accounts for the increased level 
of total apo B usually observed with atherogenic dyslipidemia.10) 
As low HDL-C rivals an elevated total apo B, it could be said that 
HDL-C is intimately involved in the atherogenic process. In addition, 
the presence of a low HDL-C level is strongly associated with the 
development of ASCVD.23)
In epidemiological studies, the onset of diabetes is accompanied 
by increased risk for ASCVD, suggesting that hyperglycemia per se 
is atherogenic.23) Examples include non-enzymatic glycosylation of 
lipids and proteins, pathogenic effects of advanced glycation prod-
ucts, increased oxidative stress, activation of protein kinase C, and 
microvascular disease of the vasa vasorum of the coronary arteri-
es.26) However, a direct role of hyperglycemia in ASCVD is still con-
troversial. Another possibility is that insulin resistance per se is in-
dependently atherogenic. The risk of ASCVD was found to be in-
creased in persons with insulin resistance.27) Still, further investiga-
tion about pathophysiology of MetS in the development of ASCVD 
is needed. 
Importance of Each Metabolic Factor
 
As mentioned above, several organizations have established 
their own diagnostic criteria for MetS such as NCEP ATP III, AHA/
NHLBI, IDF, WHO, EGIR, and ACE.6) In these diagnostic criteria of the 
MetS, different combinations of following metabolic factors are 
required, including: insulin resistance, dysglycemia, low HDL-C, hy-
pertriglyceridemia, obesity or increased waist circumference, hy-
pertension, impaired glucose tolerance or DM, microalbuminuria and 
hyperinsulinemia (Table 1). However, the importance of each meta-
bolic factor is different in each diagnostic criteria of the MetS. For 
example, the NCEP ATP III and AHA/NHLBI consider that each met-
abolic factor has the same importance.10) However, the NCEP-ATP II 
and AHA/NHLBI does not include a measure of insulin resistance, 
and it relies upon fasting glucose measurement rather than deter-
mination of glucose tolerance. The EGIR definition includes insulin 
determination as an essential component, while the IDF definition 
does not essentially require insulin resistance.7)8)28) The IDF defini-
tion requires obesity for diagnosis of MetS. This guideline explains 
that central obesity is a prerequisite for the diagnosis of the MetS, 
because it is easy to assess and independently associated with each 
of other MetS components.28) Although increased waist circumfer-
ence is an important component of MetS, some individuals with 
multiple risk factors and increased risk for certain diseases, such as 
CVD, may have normal waist circumference.29)30) Therefore, except 
for in Asians, the IDF requirement of an increased waist circumfer-
ence warranted caution because a large proportion of individuals 
with normal waist circumference have multiple risk factors addi-
tionally, and an increased risk of mortality.29) 
The WHO guidelines indicate that the presence of diabetes, im-
paired glucose tolerance, or insulin resistance is necessary for a di-
agnosis of MetS, because this condition is considered a special clas-
sification for individuals with the potential for diabetes (manifested 
as impaired glucose tolerance, impaired fasting glucose, or insulin 
resistance determined using the hyperinsulinemic-euglycemic cl-
amp).7)31) A recent study in the Japanese population revealed that 
the hazard ratio (HR) for CVD was higher among those with high 
blood glucose compared to those without high blood glucose.32) This 
finding may suggest that glucose tolerance plays an important role 
in CVD mortality. Some reports have shown higher HRs with use of 
the WHO rather than the NCEP definition of MetS. It means that the 
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participants with impaired glucose tolerance have higher HRs.33) 
Still, another study among Americans showed unadjusted and 
adjusted predictive abilities of MetS and their individual components 
for angiographic coronary artery disease (CAD). In that study, among 
metabolic factors, HDL and high fasting glucose, but not triglyceride, 
blood pressure, or BMI, were predictive of CAD in unadjusted and 
adjusted analyses.34) 
In addition, we identified HRs of each metabolic factor for IHD 
and stroke among Korean men in the MSRI study after adjusting 
for age, smoking and alcohol consumption, and exercise. For both 
IHD and stroke, higher HRs was obtained in individuals with higher 
glucose compared to the HRs in individuals with higher BMI (Fig. 1). 
It was hard to say that each metabolic factor may have the same 
importance through the findings obtained in our study using the 
MSRI cohort study. Importance of each metabolic factor was dif-
ferent in this study. It could be said that it depended on what defi-
nitions of MetS were used in predicting certain diseases such as 
CVD and other vascular diseases. However, the use of different defi-
nitions may lead to confusion regarding the diagnosis and treat-
ment of the MetS in the primary care setting when patients are be-
ing diagnosed using different criteria.13) Therefore, the use of diag-
nostic criteria of MetS must be carefully considered in accordance 
with the characteristics of specific ethnic groups. 
Apparent Threshold Effects
 
The IDF, the AHA, and the NHLBI each subsequently issued diag-
nostic criteria for the MetS. These definitions retained most of NCEP 
ATP III criteria and AHA/NHLBI suggested an adjustment of waist 
circumference to lower thresholds only in some ethnic groups, 
such as Asians, as well as lower threshold for elevated fasting glu-
cose (≥100 mg/dL).35) However, the IDF definition for other ethnic 
groups, apart from Asians, retained 3 of the 5 the NCEP ATP III diag-
nostic criteria, ie hypertension, hypertriglyceridemia, and HDL-C. The 
IDF set lower thresholds for the remaining 2 diagnostic criteria; for 
abdominal obesity (waist circumference ≥94 cm for Europid men 
and ≥80 cm for Europid women) and fasting plasma glucose {≥5.6 
mmol/L (100 mg/dL)}.34) Such threshold effects can be obtained in 
determining the association of MetS with certain diseases such as 
CVD and other vascular diseases. For example, from a study about 
MetS and incident cardiovascular morbidity and mortality in a hy-
pertensive population, hypertensive subjects with 3 or more com-
ponents of MetS had 3-fold higher risk for cardiac events, 2.59 for 
cerebrovascular and 2.26 for total cardiovascular events compared 
with those with no other components. In that study, the MetS was 
defined by the NCEP ATP III.36) 
We tried to evaluate age-adjusted and multivariable adjusted 
HRs for development of ASCVD according to the number of MetS 
components using NCEP ATP III definition in Korean men and wo-
men in the MSRI study (Fig. 2A). Both age-adjusted and multivari-
able adjusted HRs for development of ASCVD increased with incr-
easing numbers of MetS components in men and women. In a mul-
tivariable adjusted analysis, compared to those with no MetS com-
ponents, men with 3 or more components of MetS components had 
up to 3.44-fold higher risk for development of ASCVD, while wom-
en with 3 or more components of MetS components had up to 
4.42-fold higher risk for development of ASCVD. Still, there was no 
definite apparent threshold effect of the number of MetS and AS-
CVD. Similar patterns were observed in the association between MetS 
and development of IHD and stroke among Koreans in the MSRI 
study (Fig. 2B) (Table 3). Interestingly, in our findings using the MSRI 
study, when MetS was defined by either NCEP ATP III or AHA/NHL-
BI, MetS was found to be an independent risk factor for develop-
ment of IHD. However, this relationship was attenuated when we 
used IDF definition (data not shown). 
However, concerns may arise regarding pre-MetS or those having 
1 or 2 metabolic factors in the relationship with the development 
of ASCVD or IHD. Although those having 1 or 2 metabolic factors 
are considered as not having MetS, they still had increased risk of 
development of both ASCVD and IHD in the MSRI study. For exam-
ple, in the MSRI study, men and women with 1 or 2 metabolic fac-
tors had 1.5-2.3 fold higher risk of the development of ASCVD and 
IHD. From a previous study among middle-aged Japanese men, the 
multivariate-adjusted relative risk of incidence of CVD compared 
with absence of MetS components, defined by the WHO, was 3.18, 
3.48, 12.55 and 14.15 (p for trend <0.001), for presence of 1, 2, 3 and > 
or =4 MetS components, respectively. The corresponding relative 
risks of incidence of type 2 diabetes were 1.92, 4.36, 6.44 and 15.08 
(p for trend <0.001).37) There could have the possibility of misleading 
Fig. 1. HR for IHD and stroke according to the metabolic syndrome com-
ponent in Korean men in the MSRI after adjusting for age, smoking, alcohol 
consumption, and exercise (all p<0.0001). HR: hazard ratio, IHD: ischemic 
heart disease, BMI: body mass index, TG: triglyceride, HDL-C: high density lipo-
protein-cholesterol, BP: blood pressure, MSRI: Metabolic Syndrome Research 
Initiatives.
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clinicians in the treatment of individuals who had 1 or 2 metabolic 
factors.14) Therefore, in the presence of MetS, both singly and in 
combination, precede the development of ASCVD and IHD and 
participants with pre-MetS (having 1 or 2 metabolic factors) must 
not be ignored as there is no apparent threshold in defining MetS. 
Framingham Risk Score Versus Metabolic 
Syndrome
 
The FRS was initially designated to predict fatal and nonfatal co-
ronary heart disease (CHD) in the North American population, but 
this predictive model has also proven its reliability in different eth-
Fig. 2. HRs for development of ASCVD and IHD according to MetS in Korean men and women in the MRSI after adjusting for age, smoking, alcohol con-
sumption, and exercise. A: HRs for development of ASCVD according to MetS using NCEP definition. B: HRs for development of IHD according to MetS us-
ing NCEP and AHA definition. HR: hazard ratio, ASCVD: atherosclerotic cardiovascular disease, IHD: ischemic heart disease, Mets: Metabolic syndrome, 
NCEP: National Cholesterol Education Program, MSRI: Metabolic Syndrome Research Initiatives, AHA: American Heart Association.
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Table 3. HRs for development of IHD and stroke according to the number of the metabolic syndrome components in Korean men in the MSRI
IHD Stroke
HR (95% CI) -2LogL HR (95% CI) -2LogL
Model I 1.8 (1.6-1.9) 44784 1.7 (1.5-1.9) 31211
Model II 0 1.0 44694 1.0 31151
1 1.3 (1.1-1.5) 1.6 (1.3-2.0)
2 1.9 (1.6-2.2) χ2=90 1.9 (1.5-2.4) χ2=60
3 2.4 (2.0-2.8) 2.5 (2.0-3.2)
4 2.9 (2.4-3.4) p<0.01 2.9 (2.2-3.8) p<0.01
5 3.4 (2.5-4.6) 3.6 (2.4-5.5)
IHD: ischemic heart disease, HR: hazard ratio, MSRI: Metabolic Syndrome Research Initiatives
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nic groups.38) The FRS predicts the 10-year risk of CHD according to 
a gender-specific chart that includes age, smoking status, choles-
terol, systolic blood pressure, and diabetic status.39)
Metabolic syndrome is associated with a significantly increased 
risk of developing type 2 DM and CVD and has been widely promot-
ed as a means of identifying patients for lifestyle intervention to 
reduce risk factors and incident disease, in particular CVD.40) From 
previous studies, MetS was found to be inferior to the FRS in pre-
dicting either type 2 DM or CVD.14) Some recent US studies also in-
dicated that MetS is inferior to the FRS in predicting CHD.14)22)40) 
Nonetheless, MetS predicted both type 2 DM, CVD and other vas-
cular diseases.15) It has not been established whether the FRS is a 
better predictor of the risk of diseases, such as type 2 DM, CVD and 
other vascular disease than the FRS. MetS could be a good all-pur-
pose predictor compared with the FRS.15) 
From a previous study about the comparison between MetS and 
FRS for prediction of CHD, stroke and type 2 DM, the FRS was a bet-
ter predictor of CHD and stroke than the MetS but less predictive of 
type 2 DM. Areas under the receiver-operating characteristic (ROC) 
curves for FRS vs. the number of metabolic factors were 0.68 vs. 
0.59 for CHD, 0.60 vs. 0.70 for type 2 DM and 0.66 vs. 0.55 for stroke 
(p<0.001 for all).41) From another study showing whether MetS may 
improve identification of individuals at risk of CHD, comparison of 
ROC indicated that the MetS did not improve the CHD risk predic-
tion beyond the level achieved by the FRS.39) Therefore, MetS may 
be used as the first line approach to treat the risk of ASCVD or dia-
betes. In other words, MetS may complement the FRS. Still, compar-
ing the ability of predictability of MetS vs. the FRS for CVD risk is not 
a fair comparison. 
Conclusion
From a clinical or public health perspective, having a definition 
of the MetS is useful only if it identifies individuals at high risk of 
disease and particularly if it identifies individuals who are candi-
dates for a specific treatment that they would not otherwise receive. 
A prospective study of 123892 healthy Koreans within more than 
10 years revealed the substantial effects of the MetS. Our findings 
suggested that MetS is a risk factor for the development of ASCVD 
and stroke in the Korean population. There was no apparent th-
reshold relationship between the number of MetS components 
and ASCVD/stroke. However, pre-MetS or those having 1 or 2 meta-
bolic factors in relation to the risk of both ASCVD and stroke should 
be concerned as they still had increased risk for ASCVD/stroke. It 
could result in misleading clinicians in the treatment of individuals 
who had 1 or 2 metabolic factors. 
In conclusion, MetS may be used as the first line approach. Pop-
ulation based cohort studies, in particular in Japan and Korea, are 
warranted in the near future. 
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